ConductScience.org, home
A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C
API referenceFor AI assistants

Trial · NCT00922779

Adverse events70

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 70

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherAstheniaGeneral disordersRibavirin + Peginterferon Alfa-2a9056,661
otherInfluenza like illnessGeneral disordersRibavirin + Peginterferon Alfa-2a8336,661
otherPyrexiaGeneral disordersRibavirin + Peginterferon Alfa-2a3716,661
otherAnaemiaBlood and lymphatic system disordersRibavirin + Peginterferon Alfa-2a4596,661
otherWeight loss poorMetabolism and nutrition disordersRibavirin + Peginterferon Alfa-2a3436,661
seriousPyelonephritis acuteInfections and infestationsRibavirin + Peginterferon Alfa-2a26,661
seriousAcute tonsillitisInfections and infestationsRibavirin + Peginterferon Alfa-2a16,661
seriousAppendicitisInfections and infestationsRibavirin + Peginterferon Alfa-2a16,661
seriousChronic hepatitis CInfections and infestationsRibavirin + Peginterferon Alfa-2a16,661
seriousEnteritis infectiousInfections and infestationsRibavirin + Peginterferon Alfa-2a16,661
seriousFuruncleInfections and infestationsRibavirin + Peginterferon Alfa-2a16,661
seriousHepatitis GInfections and infestationsRibavirin + Peginterferon Alfa-2a16,661
seriousPneumoniaInfections and infestationsRibavirin + Peginterferon Alfa-2a16,661
seriousUrinary tract infectionInfections and infestationsRibavirin + Peginterferon Alfa-2a16,661
seriousCholecystitisHepatobiliary disordersRibavirin + Peginterferon Alfa-2a26,661
seriousCholelithiasisHepatobiliary disordersRibavirin + Peginterferon Alfa-2a26,661
seriousHepatic cirrhosisHepatobiliary disordersRibavirin + Peginterferon Alfa-2a26,661
seriousHepatic failureHepatobiliary disordersRibavirin + Peginterferon Alfa-2a26,661
seriousCholecystitis acuteHepatobiliary disordersRibavirin + Peginterferon Alfa-2a16,661
seriousHyperbilirubinaemiaHepatobiliary disordersRibavirin + Peginterferon Alfa-2a16,661

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00922779/events

API referenceFor AI assistants